During the past decade, Gastroenterologische Gemeinschaftspraxis Herne conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 5 clinical trials were completed, i.e. on average, 41.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gastroenterologische Gemeinschaftspraxis Herne" #1 sponsor was "Gilead Sciences" with 5 trials, followed by "CymaBay Therapeutics, Inc." with 3 trials sponsored, "Galapagos NV" with 3 trials sponsored, "4SC AG" with 1 trials sponsored and "HepNet Study House, German Liverfoundation" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gastroenterologische Gemeinschaftspraxis Herne" #1 collaborator was "Gilead Sciences" with 4 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Hannover Medical School" with 1 trials as a collaborator and "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Gastroenterologische Gemeinschaftspraxis Herne" are "Crohn's Disease" (3 trials), "Ulcerative Colitis" (3 trials), "Hepatitis C, Chronic" (2 trials), "Primary Biliary Cholangitis" (2 trials) and "Acute Hepatitis C" (1 trials). Many other conditions were trialed in "Gastroenterologische Gemeinschaftspraxis Herne" in a lesser frequency.

Most popular intervention types in "Gastroenterologische Gemeinschaftspraxis Herne" are "Drug" (15 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Filgotinib" (4 trials), "CT-P13" (1 trials), "Experimental: Seladelpar / MBX-8025 200 mg" (1 trials) and "Experimental: Seladelpar / MBX-8025 50 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gastroenterologische Gemeinschaftspraxis Herne" are 18 trials for "All" genders.

Currently, there are NaN active trials in "Gastroenterologische Gemeinschaftspraxis Herne". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 10 completed trials in Gastroenterologische Gemeinschaftspraxis Herne, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Gastroenterologische Gemeinschaftspraxis Herne, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".